Arecor Limited has announced dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.

AT278 is a novel proprietary formulation of concentrated insulin (500U/mL) that is designed to maintain rapid-acting characteristics in a reduced volume, thereby enabling fast absorption into the bloodstream from the site of injection.

"The initiation of the Phase I clinical trial for AT278, is key to the advancement of our diabetes franchise of superior fast acting insulins, focused on more personalized treatment regimens and sophisticated drug/device combinations. AT278 presents a significant step towards helping people with diabetes to maintain glucose control safely and conveniently. A concentrated rapid acting insulin is a key enabler to delivering the next generation of miniaturized insulin delivery systems as well as providing a superior treatment and quality of life for people requiring large daily doses of insulin to manage their condition. I look forward to reporting on the progress of AT278 next year," Sarah Howell, Chief Executive Officer at Arecor, said.